替格瑞洛片含量测定的方法学验证张园 南京中医药大学摘要： 在过去的二十年中，抗血小板聚集药物在治疗动脉粥样硬化血栓中，取得了重大的进展。
替格瑞洛片（Ticagrelor Tablets）即是成果之一。
这种由英国阿斯利康公司研制的抗血小板聚集药，商品名为倍林达（Brilinta），自2011年在美国上市，至今已有9年[1]。
随着替格瑞洛片在中国的上市，其质量控制方法的建立，被提上日程。
这篇综述旨在提供替格瑞洛片的临床应用及其含量检测的进展。
关键词：替格瑞洛片；含量测定；急性冠脉综合症；抗血小板聚集Methodological Verification of the Determination of Ticagrelor TabletsAbstract：In the past two decades, antiplatelet aggregation drugs have made significant progress in the treatment of atherothrombotic thrombosis. Ticagrelor tablets which were developed in 2010 are one of these great developments. This anti-platelet aggregation drug named ticagrelor was developed by AstraZeneca in the United Kingdom. Its product name is Brilinta,Brilinta has been listed in the United States since 2011.Ticagrelor tablets have been used to treat coronary atherosclerosis for nine years[1]. Asticagrelor tablets have already listed in China, the establishment of its quality control method needs to be put on the agenda. This review aims to provide advances in the clinical application and content testing of ticagrelor tablets.Key Words:Ticagrelor tablets; Content determination; Acute coronary syndrome; Anti-platelet aggregation引言急性冠脉综合症（acute coronary syndrome，ACS）是一组由急性心肌缺血或冠状动脉粥样硬化，斑块破裂引发血栓而形成的临床综合征，包括不稳定心绞痛以及心肌梗死，ACS占冠心病的50%以上[2]。
随着流行疾病的快速转型和主要危险因素发生率升高，冠心病近年来已成为我国主要的致死疾病之一。
研究结果显示，中国冠心病健康生命年损失约14万人年（3.7人年/千人）[3]。
ACS对中国患者和社会的疾病负担都是沉重的。
